Masimo Corp
Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. Our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life. For more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. Masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. We`re looking for people who can, do, and will make a difference.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
About Us
For more than thirty years, clinicians have trusted Masimo pulse oximetry to help improve patient outcomes. Before Masimo, pulse oximeters were unreliable, providing inaccurate measurements and frequent false alarms. Masimo revolutionized the industry with the development of Signal Extraction Technology® open paren(SET®)close paren.
SET® differentiates Masimo from other pulse oximetry technology by using advanced signal processing techniques to separate the arterial signal from sources of noise. This key advantage ensures that Masimo SET® delivers truly accurate measurements—even during conditions that prove challenging for conventional technology, such as movement and cold extremities.
- For All Skin Pigments: Masimo SET® is reliable for all skin color pigmentations.
- Accuracy Anywhere and Everywhere: Masimo SET® provides accurate measurements even in brightly lit environments, such as outdoor sunlight.
- SET® Improves Patient Outcomes: Numerous studies have shown that Masimo SET®, combined with clinical oversight, helps clinicians reduce blindness and eye damage (retinopathy of prematurity, or ROP) in neonates,reference improves critical congenital heart disease (CCHD) screening in newborns, and reduces ICU transfers and rapid response team activations on the hospital general floor.
Masimo SET® is trusted by care providers around the world to monitor more than 200 million patients each year, and has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies.